drugset / Trial / NCT02957019
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NaSingle-groupOpen-labelTreatment
Summary
Phase I/II, open-label, multicenter, prospective study.
Timeline
- Start
- 2013-07-31
- Primary completion
- 2023-09
- Completion
- 2023-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darleukin | Protein / enzyme biologic | 0.32 iu/kg | — |
| Subject | Darleukin | Protein / enzyme biologic | 0.43 iu/kg | — |
| Subject | Darleukin | Protein / enzyme biologic | 0.57 iu/kg | — |
| Subject | Darleukin | Protein / enzyme biologic | 0.76 iu/kg | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |